Viewing Study NCT00001669

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 11:07 PM

Ignite Modification Date: 2025-12-28 @ 8:44 AM

Study NCT ID: NCT00001669

Status: COMPLETED

Last Update Posted: 2008-03-04

First Post: 1999-11-03

Is Gene Therapy: True

Has Adverse Events: False

Brief Title: A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module References Module